Key facts
- It has raised $920K; the latest was Seed Round ($920K) in Nov 2025.
- Notable investors include U.K. Department of Health & Social Care, Medical Research Foundation, Moorfields Eye Charity, National Institute for Health Research Invention for Innovation, University College London.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Eye2Gene
- ·The full record, as it builds
Funding rounds
No funding rounds for Eye2Gene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eye2Gene
Developer of a precision ophthalmology platform designed to improve the diagnosis of genetic eye diseases. The company's platform offers artificial intelligence-based analysis combining imaging and genomic data, enabling eyecare professionals and pharmaceutical organizations to support earlier and more informed diagnosis.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2018
- Employees
- 4
- Website
- eye2gene.com/
- Ownership
- Privately Held (backing)
Eye2Gene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eye2Gene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eye2Gene in its N-PORT filings yet. We sweep new filings monthly.